IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from ...

PARIS & SAN JOSE, Calif.--(BUSINESS WIRE)-- LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of ...

The LimFlow system employs a covered stent that shunts oxygenated blood around a blocked artery by directing it into a nearby vein. (LimFlow) Inari Medical has signed on to a $415 million deal to ...

CLEVELAND — Cindy Elford was the first patient at University Hospitals Cleveland Medical Center to have her leg saved by the LimFlow device. We met just after the procedure. Years later, she's still ...

PARIS--(BUSINESS WIRE)--LimFlow SA, developer of minimally-invasive technology for the treatment of end-stage critical limb ischemia (CLI), a severe form of peripheral artery disease (PAD), today ...

Vascular device maker Inari Medical announced plans to buy LimFlow, a company selling a last-line therapy to save legs with blocked blood flow, on Wednesday. Inari will pay $250 million upfront and ...

PARIS--(BUSINESS WIRE)--LimFlow SA, developer of minimally-invasive technology for the treatment of end-stage critical limb ischemia (CLI), today announced completion of enrollment of the original ...

Paris, France, where LimFlow is based. (iStock/Getty Images Plus/PocholoCalapre) () LimFlow has raised $33.5 million to take its treatment for critical limb ischemia (CLI) through a pivotal trial. The ...

The US Food and Drug Administration (FDA) has approved an endovascular device for patients with chronic limb-threatening ischemia (CLTI) at risk for major amputation who are poor candidates for ...

A firm that was labeled one of Medtech’s 16 Most Promising Private Companies by Canaccord Genuity earlier this year, has strong results from a study that will help with FDA approval. LimFlow recently ...